Mittwoch, 24.06.2026, Calendar Week 26, 175. day of the year, 190 days remaining until EoY.

Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.

Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

FR0012127173

Filter zurücksetzen

Do you already know our new terminal view? Click here.

FIGI: BBG008891XD6

OSE

OSE Immunotherapeutics SA

GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH

NAME

OSE Immunotherapeutics SA

ISIN

FR0012127173

TICKER

OSE

MIC

XPAR

REUTERS

OSE.PA

BLOOMBERG

OSE FP

Mi., 24.06.2026 OSE Immunotherapeutics

Newsfeed

OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document | OSE Immunotherapeutics SA

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position | OSE Immunotherapeutics SA

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting | OSE Immunotherapeutics SA

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting | OSE Immunotherapeutics SA

OSE Immunotherapeutics Evolves its Leadership Team | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics to Present at Upcoming Investor Conferences | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces its 2026 Financial Calendar | OSE Immunotherapeutics SA

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® | OSE Immunotherapeutics SA

OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer | OSE Immunotherapeutics SA

OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab | OSE Immunotherapeutics SA

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

Half-Year Report on Liquidity Contract with Invest Securities | OSE Immunotherapeutics SA

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development | OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer | OSE Immunotherapeutics SA

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reports First Half 2025 Financial Results | OSE Immunotherapeutics SA

Appointment of Marc Le Bozec as Interim CEO | OSE Immunotherapeutics SA

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors | OSE Immunotherapeutics SA

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy | OSE Immunotherapeutics SA

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025 | OSE Immunotherapeutics SA

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court | OSE Immunotherapeutics SA

Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting | OSE Immunotherapeutics SA

Update on Information Relating to the General Meeting of September 30, 2025 | OSE Immunotherapeutics SA

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer | OSE Immunotherapeutics SA

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025 | OSE Immunotherapeutics SA

OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 | OSE Immunotherapeutics SA

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation | OSE Immunotherapeutics SA

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM | OSE Immunotherapeutics SA

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting | OSE Immunotherapeutics SA

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer | OSE Immunotherapeutics SA

Informations relatives au nombre total de droits de vote et d’actions composant le capital | OSE Immunotherapeutics SA

OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels | OSE Immunotherapeutics SA

Half-Year Report on Liquidity Contract with Invest Securities | OSE Immunotherapeutics SA